Olomoucine
CAS: 101622-51-9
Rif. 3D-FO26555
2mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione |
Informazioni sul prodotto
- N2-[(2-Hydroxyethyl)-N6-benzyladenine
- 6-(Benzylamino)-2-(2-hydroxyethylamino)-9-methylpurine
- NSC 666096
- 2-(2-Hydroxyethylamino)-6-Benzylamino-9-Methylpurine
- 2-(2′-Hydroxyethylamino)-9-methyl-6-(benzylamino)purine
- 2-(6-Benzylamino-9-methyl-9H-purin-2-ylamino)-ethanol
- 2-[[6-(Benzylamino)-9-methylpurin-2-yl]amino]ethanol
- 2-[[9-Methyl-6[(Phenylmethyl)Amino]-9H-Purin-2-Yl]Amino]-Ethanol
- 2-{[6-(benzylamino)-9-methyl-9H-purin-2-yl]amino}ethanol
- 6-Benylamino-2-(2-Hydroxyethylamino)-9-Methylpurine
- Vedi altri sinonimi
- 6-Benzylamino-2-(2-Hydroxyethylamino)-9-Methylpurine
- Ethanol, 2-[[9-methyl-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-
- N2-[(2-Hydroxyethyl)]-N6-Benzyladenine
- Olomoucine Synthetic >95%
- Olomoucine,highpurity
Olomoucine is a chemical inhibitor that binds to the ATP-binding site of the enzyme cyclin-dependent kinase 2 (CDK2) and prevents its phosphorylation of retinoblastoma protein, which leads to the inhibition of cell cycle progression. Olomoucine was shown to inhibit LPS-induced inflammatory response in vitro. It also inhibits neuronal death induced by hydrogen peroxide and glutamate in vitro. The drug has been shown to inhibit axonal growth in vitro as well as tumour cell lines. Olomoucine is also an inhibitor of drug transporters, including P-glycoprotein, with potential therapeutic benefit for cancer treatment. Olomoucine binds to mitochondrial membrane potential and inhibits neurotrophic factors such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF).